Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
Surescripts connects pharmacies, payers, PBMs, physicians, hospitals, HIEs, and EH...
Surescripts connects pharmacies, payers, PBMs, ...
PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a p...
PLUS THERAPEUTICS is a clinical-stage pharmaceu...
Kodiak Sciences is a clinical stage company developing innovative therapeutics to ...
Kodiak Sciences is a clinical stage company dev...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative biopharmaceutical company ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an in...
A patient that is diagnosed with cancer today will have a genetic screen on their ...
A patient that is diagnosed with cancer today w...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...
Join the National Investor Network and get the latest information with your interests in mind.